|
|
| |
Milestones
- 2003
|
| |
| • |
Based on best available
information, including surveys, antenatal data, and
extrapolation from comparable reference groups, AngloGold
estimated a 2003 HIV prevalence rate of 29.95% amongst its South
African workforce. In 2002, this was estimated to be 29.19%. |
| • |
Education and training
programmes continued, using a range of media particularly the
company?s induction programme, focused management training, and
peer educators. |
| • |
AHS clinics continue to treat and monitor STI cases. In 2003, 5,498
cases amongst both employees and contractors were treated1,
a decrease of 10% from the number recorded in 2002 (6,097) with
much the same population size (STI rates can be used as a proxy
measure for unprotected sex). |
| • |
Progress continued to be
made with the implementation of the VCT and Wellness programmes,
although the stigma associated with HIV/AIDS continues to hamper
these efforts. |
| |
| – |
3,269 VCT counselling sessions were conducted by
AngloGold during 2003, almost double the 1,697 that had
been recorded in 20026. |
| – |
2,903 employees registered with the AngloGold Wellness
programme during 2003. |
|
| • |
The full-scale rollout of
ART began in 2003. Some 534 employees started on the treatment
by the end of December 2003, since the start of the pilot phase
in November 2002. This equates to 18% of estimated eligible
employees. |
| • |
In 2003 the financial
impact of HIV/AIDS on AngloGold was estimated to be 1.9% of
payroll, that is R71.9 million. In 2002, it was estimated to be
1.8% (R62.5 million). This includes increased benefit payments,
training and recruitment costs due to increased staff turnover,
costs of additional health care utilisation and absenteeism
related to HIV/AIDS. It does not include diminishing
productivity whilst at work, nor the increasing costs of
maintaining productive output, which at this stage cannot be
measured. |
| • |
The average cost of
providing ART in the West Rand Region, based on costs as at
October 2003, was R1,461 per patient month on treatment. R1,101
related to variable costs for patient-contact staff time, drugs
(including their distribution and handling fees), laboratory
tests, and other medical supplies. |
| • |
Implementation in the
southern African region of an internal auditing process based on
a comprehensive risk assessment, which in 2003 focused on the
health service?s wellness programme and in 2004 will include
workplace programmes. |
|
| |
| 1 |
Excluding STIs treated at ERGO but
including employees of client companies and contractors other
than AngloGold that pay a fee to AHS for a range of health care
services. |
| 6 |
2002 VCT statistics do not include VCT
visits at ERGO which had only a small service with low volumes
at that stage. |
|
| |
|
|
|
